Announcements Trials
Browse Landscape

Phase

Phase 2 79Phase 1 30Phase 1/2 18Phase NA 10Phase EARLY_PHASE1 2Phase 4 2Phase 3 2Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Neoplasm Metastasis 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × pazopanib × Clear all
NCT01221506 2020-03-26

Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
20 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT02729194 2019-06-10

Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Completed
16 enrolled 17 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡